Protease inhibitors that overcome drug resistance

Details Protease inhibitors that overcome drug resistance Protease inhibitors that overcome drug resistance

2005-11-29

2005-11-29

Seaman, D. Margaret (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S474000, C549S475000

Reexamination Certificate

active

06969731

ABSTRACT:
HIV protease inhibitors are among the most powerful drugs in suppressing HIV in human patients. However, HIV developed resistance to all protease inhibitor drugs so far marketed or used in clinical trials. HIV generates resistance by mutating its protease. The strains of HIV containing mutant proteases less vulnerable to inhibitor drug are able to replicate better and maintain the infection. No effective principle exists for the design of resistance-proof HIV protease inhibitors (HIVPr). A new inhibitor has been developed based on a new concept for designing resistance invulnerable HIVPr inhibitors. In vitro data have shown that this inhibitor is effective against many known HIVPr mutants resistant to other HIVPr inhibitor drugs. The new concept is, therefore, generally applicable for the design of other resistance invulnerable HIVPr inhibitor drugs.

REFERENCES:
patent: 5491149 (1996-02-01), Jadhav
patent: 5683999 (1997-11-01), Jadhav et al.
patent: 0 373 497 (1990-06-01), None
patent: 09143044 (1997-06-01), None
patent: 09208450 (1997-08-01), None
patent: WO 92/03472 (1992-03-01), None
Sugiura, Contact Dermatitis, 1997, 37(2), 90, abstract only, CA 127:210184.
Carroll, Bioorg Med Chem Lett, vol 8, pp 3203-3206, 1998.
Carroll, Bioorg Med Chem Lett, vol 8, pp 2315-2320, 1998.
Baldwin, Structural Biology vol 2(3), Mar. 1995, 244-249.
Baker & Condon, “Dipeptide isosteres. 1. Synthesis of dihydroxyethylene dipeptide isosteres via diastereoselective additions of alkyllithium reagents toN,N-dimethylhydrazones. Preparations of renin and HIV-1 protease inhibitors transition-state mimics,”J Org Chem58:3277-3284 (1993).
Baker, et al., “Nonpeptide renin inhibitors employing a novel 3-Aza (or oxa)-2,4-dialkyl glutaric acid moiety as a P2/P3amide bond replacement,”J Med Chem35:1722-1734 (1992).
Bennett, et al., “The synthesis of novel HIV-protease inhibitors via silica gel assisted addition of amines to epoxides,”SYNLETT9:703-704 (1993).
Dreyer, et al., “Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of design of substrate analogue inhibitors,”Proc Natl Acad Sci. USA86:9752-9756 (1989).
Marinier, et al., “HIV-1 protease inhibitors: ketomethylene isosteres with unusually high affinity compared with hydroxyethylene isostere analogs,”Bioorganic&Medicinal Chemistry2(9):919-925 (1994).
Baldwin, et al., “Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase,”Nat. Struct. Biol.2(3):244-9 (1995).
Boger, “Renin Inhibitors. Design of Angiotensinogen Transition-state Analogs Containing Statine:Conformationally restricted inhibitors and a model for the bound conformation of renin substrate,” inAspartic Proteinases and Their Inhibitors, (Kostka, V., ed.), pp. 401-420, Walter de Gruyter:N.Y., 1985.
Carpenter, et al., “Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel,”JAMA280(1):78-86 (1998).
Carroll, et al. “Identification of potent inhibitors ofPlasmodium falciparumplasmepsin II from an encoded statine combinatorial library,”Bioorg. Med. Chem. Lett.8(17):2315-20 (1998).
Carroll, et al., “Evaluation of a structure-based statine cyclic diamino amide encoded combinatorial library against plasmepsin II and cathepsin D,”Bioorg. Med. Chem. Lett.8(22):3203-6 (1998).
Chen, et al., “Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials,”J. Biol. Chem.270(37):21433-6 (1995).
Coffin, “HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy,”Science267(5197):483-9 (1995).
Condra, et al., “Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor,” J. Virol. 70(12):8270-6 (1996).
Condra, et al., “In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors,”Nature374(6522):569-71 (1995).
Craig, et al., “Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase,”Antiviral Res.16(4):295-305 (1991).
Debouck & Metcalf, “Human Immunodeficiency Virus Protease: A target for AIDS therapy,”Drug Devel. Res.21:1-17 (1990).
Debouck, et al., “Human immunodeficiency virus protease expressed inEscherichia coliexhibits autoprocessing an specific maturation of the gag precursor,” Proc. Natl. Acad. Sci. USA 84:8903-8907 (1987).
Dorsey, et al., “L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor,”J. Med. Chem.37(21):3443-51 (1994).
Dunn, et al., “Subsite preferences of retroviral proteinases,”Methods Enzymol.241:254-178 (1994).
Ermolieff, et al., “Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in Vivo,”biochemistry36(4):12364-70 (1997).
Ghosh, et al., “3-tetrahydrofuran and pyran urethanes as high-affinity P2-ligands for HIV-1 protease inhibitors,”J. Med. Chem.36:292-94 (1993).
Ghosh, et al., “An efficient synthesis of hydroxyethylene dipeptide isosteres: The core unit of potent HIV-1 protease inhibitors,”J. Org. Chem.55:6500-3 (1991).
Graves, “Human immunodeficiency virus Proteinase: now, then, what's next?”Adv Exp Med Biol.306:395-405 (1991).
Gulnik, et al., “Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure,”biochemistry34(29):9282-7 (1995).
Ho, et al., “Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection,”Nature373(6510):123-6 (1995).
Dunn, et al., “Subsite Preferences of Retroviral Proteinases”Methods in Enzymology241:254-278 (1994).
Hong, et al., “Active-site mobility in human immunodeficiency virus, type 1, protease as demonstrated by crystal structure of A28S mutant,”Protein Sci.7(2):300-5 (1998).
Hong, et al., “Crystal structures of complexes of a peptidic inhibitor with wild-type and two mutant HIV-1 proteases,”Biochemistry35:123-126 (1996).
Hoover, et al., “Discovery of inhibitors of human renin with high oral bioavailability,”Adv Exp Med Biol.362:167-80 (1995).
Ido, et al., “Kinetic studies of human immunodeficiency virus type 1 protease and its active-site hydrogen bond mutant A28S,”J. Biol. Chem.266(36):24359-66 (1991).
Jacobsen, et al., “Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959,”Virology206(1):527-34 (1995).
Jacobsen, et al., “In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies,”J. Infect. Dis.173(6):1379-87 (1996).
Kempf, et al., “ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans,”Proc. Natl. Acad. Sci. U S A.92(7):2484-8 (1995).
Kohl, et al., “Active human immunodeficiency virus protease is required for viral infectivity,”Proc. Natl. Acad. Sci. USA85(13):4686-90 (1988).
Lapatto, et al., “X-ray analysis of HIV-1 proteinase at 2.7 A resolution confirms structural homology among retroviral enzymes,”Nature342(6247):299-302 (1989).
Lin, et al., “Effect of point mutations on the kinetics and the inhibition of human immunodeficiency type 1 protease: Relationship to drug resistance,”Biochemistry34:1143-1152 (1995).
Majer, et al., “Structural based subsite specificity mapping of human cathepsin D using statine-based inhibitors,”Protein Sci.6(7):1458-66 (1997).
Marciniszyn, et al., “Mode of inhibition of acid proteases by pepstatin,”J. Biol. Chem.251(22):7088-94 (1976).
Mellors, “Closing in on human immunodeficiency virus

Affiliated with

Also associated with

Rating

Protease inhibitors that overcome drug resistance does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Protease inhibitors that overcome drug resistance, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protease inhibitors that overcome drug resistance will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3519407